BE1001425A4 - Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association. - Google Patents

Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association. Download PDF

Info

Publication number
BE1001425A4
BE1001425A4 BE8700510A BE8700510A BE1001425A4 BE 1001425 A4 BE1001425 A4 BE 1001425A4 BE 8700510 A BE8700510 A BE 8700510A BE 8700510 A BE8700510 A BE 8700510A BE 1001425 A4 BE1001425 A4 BE 1001425A4
Authority
BE
Belgium
Prior art keywords
gly
ser
leu
arg
cys
Prior art date
Application number
BE8700510A
Other languages
English (en)
French (fr)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/862,057 external-priority patent/US4976959A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of BE1001425A4 publication Critical patent/BE1001425A4/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE8700510A 1986-05-12 1987-05-11 Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association. BE1001425A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86204686A 1986-05-12 1986-05-12
US06/862,057 US4976959A (en) 1986-05-12 1986-05-12 T-PA and SOD in limiting tissue damage

Publications (1)

Publication Number Publication Date
BE1001425A4 true BE1001425A4 (fr) 1989-10-31

Family

ID=27127662

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8700510A BE1001425A4 (fr) 1986-05-12 1987-05-11 Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association.

Country Status (13)

Country Link
JP (1) JPH0680015B2 (xx)
AU (1) AU600724B2 (xx)
BE (1) BE1001425A4 (xx)
CH (1) CH672989A5 (xx)
DE (1) DE3715662A1 (xx)
DK (1) DK237187A (xx)
FR (1) FR2600895B1 (xx)
GB (1) GB2194886B (xx)
IE (1) IE59895B1 (xx)
LU (1) LU86875A1 (xx)
NL (1) NL8701113A (xx)
NZ (1) NZ220260A (xx)
SE (1) SE8701921L (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780784B2 (ja) * 1987-10-23 1995-08-30 宇部興産株式会社 微小循環障害に基づく心筋虚血傷害治療薬
NZ230808A (en) * 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
DE4038563A1 (de) * 1990-12-04 1992-06-11 Gruenenthal Gmbh Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma
DE19518625C2 (de) * 1995-05-24 1997-08-07 Buescher Pebueso Beton Verfahren zum Abdichten von Betonrohren und ein für die Durchführung des Verfahrens geeignetes Betonrohr
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
WO2011013668A1 (ja) * 2009-07-27 2011-02-03 国立大学法人新潟大学 虚血性イベントの治療用医薬品組成物
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0112122A2 (en) * 1982-12-14 1984-06-27 South African Inventions Development Corporation Plasminogen activator
EP0123304A2 (en) * 1983-04-21 1984-10-31 Asahi Kasei Kogyo Kabushiki Kaisha A method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same
GB2176703A (en) * 1985-05-28 1987-01-07 Wellcome Found Tissue plasminogen activator
GB2176702A (en) * 1985-05-28 1987-01-07 Wellcome Found Tissue plasminogen activator

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
WO1987006831A1 (en) * 1986-05-15 1987-11-19 Emory University Composition and method for treating a thrombus and embolus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0112122A2 (en) * 1982-12-14 1984-06-27 South African Inventions Development Corporation Plasminogen activator
EP0123304A2 (en) * 1983-04-21 1984-10-31 Asahi Kasei Kogyo Kabushiki Kaisha A method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same
GB2176703A (en) * 1985-05-28 1987-01-07 Wellcome Found Tissue plasminogen activator
GB2176702A (en) * 1985-05-28 1987-01-07 Wellcome Found Tissue plasminogen activator

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS/RRM, AN-28103065; A.S. HESTER: "Superoxide dismutase gets hotter at bio-technology general", & GENET. TECHNOL. NEWS, 1985, vol. 5, no. 1, p2 *
DIALOG 86-06166 PHARMACEUTICAL NEWS INDEX: FDC REPORTS: "The Pink Sheet", vol. 48, no. 5, pages 8-10 *

Also Published As

Publication number Publication date
IE871210L (en) 1987-11-12
DK237187D0 (da) 1987-05-11
GB8711058D0 (en) 1987-06-17
DE3715662A1 (de) 1987-11-19
NL8701113A (nl) 1987-12-01
AU600724B2 (en) 1990-08-23
LU86875A1 (fr) 1988-01-20
SE8701921L (sv) 1987-11-13
FR2600895A1 (fr) 1988-01-08
JPH0680015B2 (ja) 1994-10-12
SE8701921D0 (sv) 1987-05-11
CH672989A5 (xx) 1990-01-31
GB2194886B (en) 1990-04-25
GB2194886A (en) 1988-03-23
FR2600895B1 (fr) 1993-12-24
AU7270487A (en) 1987-11-19
IE59895B1 (en) 1994-04-20
NZ220260A (en) 1990-07-26
JPS6322026A (ja) 1988-01-29
DK237187A (da) 1987-11-13

Similar Documents

Publication Publication Date Title
BE1001425A4 (fr) Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association.
FR2593393A1 (fr) Solution aqueuse a usage parenteral d'activateur tissulaire du plasminogene, procede pour la preparer et recipient obture la contenant
EP0115974B1 (fr) Préparation à activité collagénolytique ayant une activité élevée et compositions pharmaceutiques la contenant
LU86444A1 (fr) Nouvelle compostion d'activateur tissulaire du plasminogene
AU607303B2 (en) Composition of anticoagulants
HU224826B1 (en) Activated protein c formulations
FR2591485A1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
US4976959A (en) T-PA and SOD in limiting tissue damage
EP0346241B1 (fr) Procédé de préparation d'une fraction concentrée en facteur Vlla et son application à titre de médicament
US20110053851A1 (en) Haemostasis-modulating compositions and uses therefor
JPH0273022A (ja) 組織プラスミノーゲン活性化因子を用いた薬学的製剤
JP2916947B2 (ja) Ｃｐｂ―ｉの安定化方法及び製剤組成物
CA1282002C (en) Pharmaceutical composition comprising t-pa and oxypurinol
CN1320922C (zh) 基于用丙二烯氧合酶将脂质过氧化物酶消除的心脏保护疗法
FR2605225A1 (fr) Compositions pharmaceutiques a base d'urokinase
FR2495634A1 (fr) Enzyme nouvelle et utilisable en therapeutique
CA1232542A (fr) Preparation a activite collagenolytique ayant une activite elevee et compositions pharmaceutiques la contenant
JPH05368B2 (xx)
FR2538702A1 (fr) Preparation a activite collagenolytique ayant une activite elevee et compositions phamaceutiques la contenant
Takahashi et al. Urokinase-type plasminogen activator/receptor and a metalloproteinase-mediated process of tissue destruction by cell colonies of a metastatic carcinomatousline growing in collagen gel
FR2538701A1 (fr) Preparation a activite collagenolytique ayant une activite elevee et compositions pharmaceutiques la contenant
FR2688786A1 (fr) Polypeptide a activite thrombolytique.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Effective date: 19960531